Calithera Biosciences Inc. (CALA) Sees Unusually-High Trading Volume
Calithera Biosciences Inc. (NASDAQ:CALA) saw unusually-strong trading volume on Friday . Approximately 191,672 shares changed hands during mid-day trading, a decline of 8% from the previous session’s volume of 207,369 shares.The stock last traded at $3.65 and had previously closed at $3.61.
A number of analysts recently weighed in on CALA shares. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Tuesday, March 22nd. JMP Securities restated a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $10.48.
The stock has a 50-day moving average of $4.56 and a 200 day moving average of $5.41. The stock’s market capitalization is $68.81 million.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. Equities analysts predict that Calithera Biosciences Inc. will post ($2.15) EPS for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.